Why is Humira so expensive?
In recent years, the high price of Humira, one of the best-selling drugs in the world, has been controversial. This article will combine the hot topics and hot content on the Internet in the past 10 days, analyze the reasons for the high price of Humira from multiple angles, and display relevant background information through structured data.
1. Basic information about Humira
Humira is a biological agent used to treat autoimmune diseases. Its main ingredient is Adalimumab. It is widely used in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis and other diseases. The following is Humira’s market performance data:
| indicator | data |
|---|---|
| Global sales (2022) | $21.2 billion |
| US market price (40mg/0.8ml) | About US$6,000/piece |
| Chinese market price (40mg/0.8ml) | About 3,000 yuan/piece |
| Patent protection period | Expires 2023 (US) |
2. Reasons for the high price of Humira
1.R&D costs are high
The research and development of biological agents requires huge financial investment and a long clinical trial cycle. According to statistics, Humira’s research and development costs exceed US$2 billion, and these costs will eventually be passed on to drug prices.
2.Patent protection mechanism
AbbVie has applied for 247 patents for Humira through its "patent jungle" strategy, forming a tight patent protection network that effectively prevents competition from generic drugs. The following are key points in time for Humira patent protection:
| Patent type | Expiration time |
|---|---|
| compound patent | 2016 |
| Preparation patent | 2022 |
| Usage method patent | 2023 |
3.Strong market demand
Humira has a wide range of indications, and more than 1 million patients worldwide rely on this drug for treatment. Strong market demand allows pharmaceutical companies to maintain a high-price strategy.
4.Medical insurance reimbursement mechanism
In developed countries such as the United States, Humira is mainly reimbursed through commercial insurance and medical insurance, and the patient out-of-pocket ratio is low, which also reduces price sensitivity.
3. Recent hot discussions
1.Impact of generic drug launches
As Humira’s patent expires, many pharmaceutical companies have launched biosimilars. The following is the status of recently approved Humira biosimilars:
| Drug name | Manufacturing company | time to market |
|---|---|---|
| Amjevita | Amgen | January 2023 |
| Cyltezo | Boehringer Ingelheim | July 2023 |
| Hyrimoz | Novartis | October 2023 |
2.price adjustment strategy
In the face of generic competition, AbbVie has taken a variety of measures to maintain market share, including:
- Launch of patient assistance program
- Sign exclusive agreements with insurance companies
- Slightly lower drug prices
3.Price differences between countries
The price of Humira in different countries varies significantly, which is mainly related to the drug pricing policies and medical insurance systems of each country:
| Country/Region | Price (40mg/0.8ml) |
|---|---|
| USA | About $6,000 |
| United Kingdom | Approximately £1,200 |
| Canada | Approximately $2,000 CAD |
| China | About 3,000 yuan |
4. Future Outlook
As more biosimilars come on the market, the price of Humira is expected to gradually decrease. However, considering the production complexity and brand effect of biologics, prices will remain high in the short term. Industry experts predict that the market size of Humira and its biosimilars will reach US$25 billion by 2025.
Drug price issues involve many aspects such as research and development innovation, patient accessibility, and medical insurance sustainability. It requires the government, enterprises, and all sectors of society to work together to find a balance point.
check the details
check the details
en
